Seegnal’s first deployment in United Arab Emirates

Abu Dhabi Stem Cells Center (ADSCC) and Seegnal eHealth Ltd (Seegnal) have signed an Integration, Licensing and Collaboration Agreement to deploy Seegnal’s innovative and globally groundbreaking clinical decision support platform as their drug-related problems (DRPs) solution.

DRPs cause huge health and financial burden across the globe (e.g., the 4th mortality cause in the US) and thus, DRPs assessment is routinely mandated at the point-of-care (e.g., hospitals, clinics) and when dispensing medications (e.g., pharmacies). However, current solutions are massively (>98%) overridden by clinicians due to lack of personalization, high (>98%) percentage of false alerts, being unbearably time consuming and due to their inability to assess up to 50% of critical patient data.

The Abu Dhabi-based ADSCC is a world-renowned provider of advanced medical services and treatments. Its goal is to provide state-of-the art medical care, to enhance patient-specific treatments (e.g., by leveraging pharmaco-genetic assessments, AI/ML), cellular therapies and regenerative techniques to the people of UAE and the surrounding regions.

Founded in March 2019 to meet growing domestic and regional demand for highly specialized medical services and treatments, ADSCC is equipped with the latest technology and medical devices that are unique to the region. ADSCC played a huge part in successfully battling COVID-19 pandemic in UAE and is also a home to AD-BMT – a bone marrow transplant procedure unique to the region, that has been successfully performed on the premises of Abu Dhabi Stem Cells Center.

The Center focuses primarily on harvesting, processing, characterizing and storing cell products for clinical application in both regenerative medicine and hematopoietic transplantation, along with aiming to streamline and develop new processes related to stem cell therapy and research.

Seegnal’s platform optimizes the clinicians’ workflow by providing quick, patient-specific, safe and efficient medication prescription. It substantially and innovatively overcomes all the above-mentioned challenges by real-time consideration of the widest scope of DRP data, including hundreds of exclusive patient and medication data elements (e.g., active ingredients, dose-response curves, lab results, pharmaco-kinetic properties, diet, smoking, ECG) while utilizing personalized algorithms with groundbreaking efficiency, unmatched accuracy and patient-tailored assessments.

In addition to all of the above, Seegnal also incorporates unique and exclusive PK pharmaco-genetic capabilities (that substantially impact 10-20% of the general population) and empowers clinicians to manage and resolve patient-specific DRPs fully, quickly and effectively.

Both parties envision the way forward as a path to enhance their collaboration,  expand their business both locally and regionally while providing state-of-the-art patient-specific medicine.

For more information, please contact us here. Stay updated and follow us on LinkedIn!